

SAFETY DATA SHEET

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name OSPHOS 51 MG/ML SOLUTION FOR INJECTION FOR HORSES (NZ)

Synonyms OSPHOS 51 MG/ML INJECTION

1.2 Uses and uses advised against

Uses VETERINARY USE

Uses advised against Not for human use. Not to be used in horses intended for human consumption.

1.3 Details of the supplier of the product

Supplier nameDECHRA VETERINARY PRODUCTS NZ LTDAddressPO Box 1604, Paraparaumu Beach, 5252, NEW ZEALANDTelephone0800 473 838Emailinfo.nz@dechra.comWebsitehttp://www.dechra.co.nz/

1.4 Emergency telephone numbers

Emergency 0800 764 766 (National Poisons Centre NZ)

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

HAZARDOUS ACCORDING TO NZ ENVIRONMENTAL PROTECTION AUTHORITY CRITERIA

Physical Hazards

Not classified as a Physical Hazard

Health Hazards

Toxic to Reproduction: Category 2

Environmental Hazards

Not classified as an Environmental Hazard

2.2 GHS Label elements

Signal word

Pictograms

WARNING



Hazard statements

H361fd

Suspected of damaging fertility. Suspected of damaging the unborn child.

Prevention statements

P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P280	Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.

Response statements

P308 + P313

IF exposed or concerned: Get medical advice/ attention.



PRODUCT NAME OSPHOS 51 MG/ML SOLUTION FOR INJECTION FOR HORSES (NZ)

Storage statements

P405

Store locked up.

Disposal statements

P501

Dispose of contents/container in accordance with relevant regulations.

2.3 Other hazards

No information provided.

3. COMPOSITION/ INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content
DICHLOROMETHYLENEDIPHOSPHONIC ACID SODIUM SALT	22560-50-5	245-078-9	6%
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder

4. FIRST AID MEASURES

4.1 Description of first aid measures

Eye	If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.
Inhalation	If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
Skin	If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.
Ingestion	For advice, contact the National Poisons Centre on 0800 764 766 (0800 POISON) or +643 479 7248 or a doctor (at once). If swallowed, do not induce vomiting.
First aid facilities	None allocated

First aid facilities None allocated.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve toxic gases if strongly heated.

5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

6.2 Environmental precautions

Prevent product from entering drains and waterways.



PRODUCT NAME OSPHOS 51 MG/ML SOLUTION FOR INJECTION FOR HORSES (NZ)

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well marked area, removed from foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 30°C.

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

No biological limit values have been entered for this product.

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.

PPE

Eye / Face	When using large quantities or where heavy contamination is likely, wear splash-proof goggles.
Hands	Wear latex gloves.
Body	In a laboratory situation, wear a laboratory coat.
Respiratory	Not required under normal conditions of use.



9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance	CLEAR LIQUID
Odour	SLIGHT ODOUR
Flammability	NON FLAMMABLE
Flash point	NOT RELEVANT
Boiling point	NOT AVAILABLE
Melting point	NOT AVAILABLE
Evaporation rate	NOT AVAILABLE
рН	3.8 to 4.5
Vapour density	NOT AVAILABLE
Relative density	NOT AVAILABLE
Solubility (water)	SOLUBLE
Vapour pressure	NOT AVAILABLE
Upper explosion limit	NOT RELEVANT
Lower explosion limit	NOT RELEVANT

ChemAlert.

PRODUCT NAME OSPHOS 51 MG/ML SOLUTION FOR INJECTION FOR HORSES (NZ)

9.1 Information on basic physical and chemical properties

Partition coefficient	NOT AVAILABLE
Autoignition temperature	NOT AVAILABLE
Decomposition temperature	NOT AVAILABLE
Viscosity	NOT AVAILABLE
Explosive properties	NOT AVAILABLE
Oxidising properties	NOT AVAILABLE
Odour threshold	NOT AVAILABLE

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Hazardous polymerisation is not expected to occur.

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources.

10.5 Incompatible materials

Compatible with most commonly used materials.

10.6 Hazardous decomposition products

May evolve toxic gases if heated to decomposition.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity	This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.
Skin	Exposure considered unlikely. Due to product form, adverse health effects via skin contact are not anticipated. However, accidental injection into the skin (needle stick injury) may result in a local injection site reaction.
Еуе	Exposure to contents is considered unlikely. Due to product form and nature of use, the potential for exposure is reduced. However, if unit is damaged contact may result in irritation and lacrimation.
Sensitisation	Not classified as causing skin or respiratory sensitisation.
Mutagenicity	Not classified as a mutagen.
Carcinogenicity	Not classified as a carcinogen.
Reproductive	Suspected of damaging fertility or the unborn child. In rat studies, disodium clodronate is shown to have detrimental effects during pregnancy.
STOT - single exposure	Not classified as causing organ damage from single exposure. Due to the product form, exposure to contents is not anticipated. However, high level exposure may result in respiratory irritation, drowsiness, dizziness, nausea and headache.
STOT - repeated exposure	Not classified as causing organ damage from repeated exposure.
Aspiration	Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No information provided.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.



12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No information provided.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal For small quantities, collect and place in sealable containers. Dispose of, as with other clinical waste, by high temperature incineration (recommended > 1100°C). Burial to landfill may be acceptable, but only at an approved and licensed waste disposal site.

Legislation Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD ACCORDING TO LAND TRANSPORT RULE: DANGEROUS GOODS 2005; NZS 5433:2012, UN, IMDG OR IATA

	LAND TRANSPORT (NZS 5433)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code None allocated.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Approval code HSR100757

Group standard Veterinary Medicines (Limited Pack Size, Finished Dose) Group Standard 2020

ACVM Number A011429

 Inventory listings
 AUSTRALIA: AIIC (Australian Inventory of Industrial Chemicals)

 All components are listed on AIIC, or are exempt.
 NEW ZEALAND: NZIOC (New Zealand Inventory of Chemicals)

 All components are listed on the NZIoC inventory, or are exempt.
 All components are listed on the NZIOC inventory, or are exempt.

16. OTHER INFORMATION

Additional information PERSONAL PROTECTIVE EQUIPMENT GUIDELINES: The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.

ChemAlert.

PRODUCT NAME	OSPHOS 51 MG/ML	SOLUTION FOR INJECTION FOR HORSES (NZ)		
Abbreviations	ACGIH CAS # CCID CNS EC No. EMS EPA GHS HSNO IARC LC50 LD50 mg/m ³ OEL pH ppm STEL STOT-RE STOT-RE STOT-SE TLV TWA	American Conference of Governmental Industrial Hygienists Chemical Abstract Service number - used to uniquely identify chemical compounds Chemical Classification and Information Database (HSNO) Central Nervous System EC No - European Community Number Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous Goods) Environmental Protection Authority [New Zealand] Globally Harmonized System Hazardous Substances and New Organisms International Agency for Research on Cancer Lethal Concentration, 50% / Median Lethal Concentration Lethal Dose, 50% / Median Lethal Dose Milligrams per Cubic Metre Occupational Exposure Limit relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly alkaline). Parts Per Million Short-Term Exposure Limit Specific target organ toxicity (repeated exposure) Specific target organ toxicity (single exposure) Threshold Limit Value Time Weighted Average		
Report status	product and s It is based of manufacturer, the current sta at the time of directly from t While RMT ha not provide at no liability for	This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS'). It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier. While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.		
Prepared by	5 Ventnor Äve Western Aust Phone: +61 8 Fax: +61 8 93 Email: info@r	Risk Management Technologies 5 Ventnor Ave, West Perth Western Australia 6005 Phone: +61 8 9322 1711 Fax: +61 8 9322 1794 Email: info@rmt.com.au Web: www.rmtglobal.com		

[End of SDS]

